EP3914265A4 - B-zell-immuntherapie - Google Patents
B-zell-immuntherapie Download PDFInfo
- Publication number
- EP3914265A4 EP3914265A4 EP20745872.0A EP20745872A EP3914265A4 EP 3914265 A4 EP3914265 A4 EP 3914265A4 EP 20745872 A EP20745872 A EP 20745872A EP 3914265 A4 EP3914265 A4 EP 3914265A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell immunotherapy
- immunotherapy
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962795629P | 2019-01-23 | 2019-01-23 | |
US201962837765P | 2019-04-24 | 2019-04-24 | |
PCT/US2020/014836 WO2020154534A1 (en) | 2019-01-23 | 2020-01-23 | B cell immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3914265A1 EP3914265A1 (de) | 2021-12-01 |
EP3914265A4 true EP3914265A4 (de) | 2023-02-01 |
Family
ID=78232398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20745872.0A Pending EP3914265A4 (de) | 2019-01-23 | 2020-01-23 | B-zell-immuntherapie |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3914265A4 (de) |
CN (1) | CN113677354A (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115393351B (zh) * | 2022-10-27 | 2023-01-24 | 北京大学第三医院(北京大学第三临床医学院) | 一种基于朗格汉斯细胞判断角膜免疫状态的方法及装置 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019178613A1 (en) * | 2018-03-16 | 2019-09-19 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4988204B2 (ja) * | 2004-02-09 | 2012-08-01 | 田辺三菱製薬株式会社 | 筋萎縮性側索硬化症(als)又はalsに起因する疾患の新規治療剤 |
EP1877544B1 (de) * | 2005-04-18 | 2011-12-14 | ACTX, Inc. | Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe |
US20100028296A1 (en) * | 2005-05-02 | 2010-02-04 | Chavez Raymond A | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
WO2009131712A2 (en) * | 2008-04-25 | 2009-10-29 | Duke University Medical Center | Regulatory b cells and their uses |
WO2011147622A1 (en) * | 2010-05-26 | 2011-12-01 | Deutsches Rheuma-Forschungszentrum Berlin | Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells |
-
2020
- 2020-01-23 EP EP20745872.0A patent/EP3914265A4/de active Pending
- 2020-01-23 CN CN202080021588.2A patent/CN113677354A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019178613A1 (en) * | 2018-03-16 | 2019-09-19 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
Non-Patent Citations (5)
Title |
---|
A. RAY ET AL: "A Novel IL-10-Independent Regulatory Role for B Cells in Suppressing Autoimmunity by Maintenance of Regulatory T Cells via GITR Ligand", THE JOURNAL OF IMMUNOLOGY, vol. 188, no. 7, 1 April 2012 (2012-04-01), pages 3188 - 3198, XP055034451, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1103354 * |
BODHANKAR SHEETAL ET AL: "IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke", METABOLIC BRAIN DISEASE, vol. 28, no. 3, 1 September 2013 (2013-09-01), US, pages 375 - 386, XP055960801, ISSN: 0885-7490, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s11011-013-9413-3.pdf> DOI: 10.1007/s11011-013-9413-3 * |
MILO RON ET AL: "Therapies for multiple sclerosis targeting B cells", CROATIAN MEDICAL JOURNAL, vol. 60, no. 2, 1 April 2019 (2019-04-01), CR, pages 87 - 98, XP055960892, ISSN: 0353-9504, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509632/pdf/CroatMedJ_60_0087.pdf> DOI: 10.3325/cmj.2019.60.87 * |
PENNATI ANDREA ET AL: "Adoptive transfer of IL-10+regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model", CELLULAR & MOLECULAR IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 15, no. 7, 8 January 2018 (2018-01-08), pages 727 - 730, XP036854777, ISSN: 1672-7681, [retrieved on 20180108], DOI: 10.1038/CMI.2017.152 * |
See also references of WO2020154534A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN113677354A (zh) | 2021-11-19 |
EP3914265A1 (de) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3817131A4 (de) | Batterie | |
EP3925297A4 (de) | Primärzellenwechsel | |
EP3966316A4 (de) | Modifizierte pluripotente zellen | |
EP3918048A4 (de) | Durchflusszellen | |
EP3949998A4 (de) | Zellaktivator | |
EP3805270A4 (de) | Verbesserte anti-cd19-car-t-zelle | |
EP3930031A4 (de) | Batterie | |
EP3823639A4 (de) | Auf msc und exosom basierende immuntherapie | |
EP3996179A4 (de) | Batterie | |
EP3909590A4 (de) | Zelluläre immuntherapiekombination | |
EP3918050A4 (de) | Durchflusszellen | |
EP3962955A4 (de) | Antigenspezifische gegen cd19 gerichtete car-t-zellen | |
EP4005327A4 (de) | Techniken zur zellenauswahl für duale konnektivität | |
EP3993798A4 (de) | Neuartige verfahren | |
EP3893285A4 (de) | Solarzelle | |
EP4018510A4 (de) | Batterie | |
EP3998660A4 (de) | Batterie | |
EP3966235A4 (de) | Manipulierte t-zellen | |
EP3951962A4 (de) | Festelektrolyt | |
EP3958336A4 (de) | Solarzelle | |
EP3806894A4 (de) | Plap-car-effektorzellen | |
EP3780136A4 (de) | Zelle | |
EP4047694A4 (de) | Batterie | |
EP4034119A4 (de) | Neuartige verfahren | |
EP4007655A4 (de) | Durchflusszellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210817 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HOLY CROSS HOSPITAL, INC. Owner name: THE GENERAL HOSPITAL CORPORATION |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0781 20100101ALI20220920BHEP Ipc: A61P 25/28 20060101ALI20220920BHEP Ipc: A61K 35/12 20150101AFI20220920BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230105 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0781 20100101ALI20221223BHEP Ipc: A61P 25/28 20060101ALI20221223BHEP Ipc: A61K 35/12 20150101AFI20221223BHEP |